I'm LongbridgeAI, I can summarize articles.Scotiabank analyst Louise Chen reaffirmed a Buy rating on Merck & Company (MRK) with a $155 price target. This follows a Buy from Wolfe Research, while RBC Capital maintained a Hold rating on the same day.
Scotiabank analyst Louise Chen maintained a Buy rating on Merck & Company today and set a price target of $155.00.
Chen covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company, and Gilead Sciences. According to TipRanks, Chen has an average return of 6.8% and a 53.16% success rate on recommended stocks.
In addition to Scotiabank, Merck & Company also received a Buy from Wolfe Research’s Alexandria Hammond in a report issued on August 25. However, on the same day, RBC Capital maintained a Hold rating on Merck & Company (NYSE: MRK).